Cardiol Therapeutics Inc Class A
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
- Ticker
- CRDL
- Trading on
- NASDAQ
- ISIN
- CA14161Y2006
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- David G. Elsley MBA
- Headquarters
- 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5
- Employees
- 18
- Website
- cardiolrx.com
Metrics
Analyst Insights & forecasts
Based on information from 6 analysts.
Earnings per share (EPS) forecast
| Q4 • 25 | Q1 • 26 | Q2 • 26 | |
|---|---|---|---|
| Actual | -$0.07 | -$0.05 | -$0.04 |
| Expected | -$0.11 | -$0.08 | -$0.09 |
| Surprise | 36.36% | 37.53% | 55.56% |
| Beat | Beat | Current |
Financial Performance
| Q2 • 26 | Q3 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $0M | - | NaN% |
| Net income | $-8.6M | $-13M | 50.14% |
| Profit margin | -∞% | 0.00% | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a Cardiol Therapeutics Inc Class A share?
Cardiol Therapeutics Inc Class A shares are currently traded for undefined per share.
02How many shares does Cardiol Therapeutics Inc Class A have?
Cardiol Therapeutics Inc Class A currently has 128M shares.
03Does Cardiol Therapeutics Inc Class A pay dividends?
No, Cardiol Therapeutics Inc Class A doesn't pay dividends.
04What is Cardiol Therapeutics Inc Class A 52 week high?
Cardiol Therapeutics Inc Class A 52 week high is $2.34.
05What is Cardiol Therapeutics Inc Class A 52 week low?
Cardiol Therapeutics Inc Class A 52 week low is $0.88.
06What is the 200-day moving average of Cardiol Therapeutics Inc Class A?
Cardiol Therapeutics Inc Class A 200-day moving average is $1.30.
07Who is Cardiol Therapeutics Inc Class A CEO?
The CEO of Cardiol Therapeutics Inc Class A is David G. Elsley MBA.
08How many employees Cardiol Therapeutics Inc Class A has?
Cardiol Therapeutics Inc Class A has 18 employees.
09What is the market cap of Cardiol Therapeutics Inc Class A?
The market cap of Cardiol Therapeutics Inc Class A is $128M.
10What is the P/E of Cardiol Therapeutics Inc Class A?
The current P/E of Cardiol Therapeutics Inc Class A is null.
11What is the EPS of Cardiol Therapeutics Inc Class A?
The EPS of Cardiol Therapeutics Inc Class A is -$0.25.
12What is the PEG Ratio of Cardiol Therapeutics Inc Class A?
The PEG Ratio of Cardiol Therapeutics Inc Class A is null.
13What do analysts say about Cardiol Therapeutics Inc Class A?
According to the analysts Cardiol Therapeutics Inc Class A is considered a buy.


